ACTH-secreting Crooke cell carcinoma of the pituitary

European Journal of Clinical Investigation

Volumn 43, Issue 1, 2013, Pages 20-26

  Kovács, Gábor L ^a   Góth, Miklós ^a   Rotondo, Fabio ^b   Scheithauer, Bernd W ^c   Carlsen, Eivind ^d   Saadia, Ali ^d   Hubina, Erika ^a   Kovács, László ^a   Szabolcs, István ^a   Nagy, Pál ^e   Czirják, Sándor ^f   Hanzély, Zoltán ^f   Kovács, Kálmán ^b   Horváth, Éva ^b   Korbonits, Márta ^d  

^a State Health Center Military Hospital   (Hungary)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MAYO CLINIC   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Vaszary Kolos Hospital   (Hungary)

^f NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

Author keywords

Cushing disease; Nelson syndrome; Pituitary adenoma; Pituitary carcinoma; Pituitary pathology

Indexed keywords

CORTICOTROPIN; CYCLIN D1; FOLLITROPIN; GROWTH HORMONE; HYDROCORTISONE; IODOCHOLESTEROL; KI 67 ANTIGEN; LUTEINIZING HORMONE; PROTEIN P27; PROTEIN P53; TETRAXETAN; THYROTROPIN; YTTRIUM 90;

ADOLESCENT; ADRENALECTOMY; ANTIBODY LABELING; ARTICLE; AUTOPSY; CANCER RADIOTHERAPY; CASE REPORT; CAUSE OF DEATH; CELL TYPE; CLINICAL FEATURE; CROOKE CELL MACROADENOMA OF THE PITUITARY; CUSHING DISEASE; DISEASE COURSE; DISTANT METASTASIS; ELECTRON MICROSCOPY; FEMALE; FOLLOW UP; GALACTORRHEA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCORTISOLISM; HYPOPHYSIS TUMOR; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MITOSIS; NECK METASTASIS; NELSON SYNDROME; PRIORITY JOURNAL; RADIATION DOSE; SKIN DISCOLORATION; TRANSSPHENOIDAL SURGERY; TUMOR CELL; TUMOR VOLUME; VISUAL FIELD;

ACTH-SECRETING PITUITARY ADENOMA; ADOLESCENT; ADRENALECTOMY; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; FEMALE; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; NELSON SYNDROME; NEOPLASM METASTASIS; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PITUITARY NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84871609768     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12010     Document Type: Article

References (29)

1. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-99.
2. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986;65:733-44.
3. Heaney AP. Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 2011;96:3649-60.
4. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 1997;79:804-12.
5. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 1980;98:617-38.
6. Scheithauer BW, Fereidooni F, Horvath E, Kovacs K, Robbins P, Tews D et al. Pituitary carcinoma: an ultrastructural study of eleven cases. Ultrastruct Pathol 2001;25:227-42.
7. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 2007;38:185-9.
8. Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999;84:3823-30.
9. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008;93:2390-401.
10. Kawashima ST, Usui T, Sano T, Iogawa H, Hagiwara H, Tamanaha T et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol (Oxf) 2009;70:656-7.
11. Crooke AC, Russel D. A change in the basophil cells of the pituitary gland common conditions which exhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol 1935;41:339-49.
12. George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV et al. Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 2003;27:1330-6.
13. Nelson DH, Meakin JW, Dealy JB Jr, Matson DD, Emerson K Jr, Thorn GW. ACTH-producing tumor of the pituitary gland. N Engl J Med 1958;259:161-4.
14. Barber TM, Adams E, Ansorge O, Byrne JV, Karavitaki N, Wass JA. Nelson's syndrome. Eur J Endocrinol 2010;163:495-507.
15. Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1995;80:165-71.
16. Pereira MA, Halpern A, Salgado LR, Mendonca BB, Nery M, Liberman B et al. A study of patients with Nelson's syndrome. Clin Endocrinol (Oxf) 1998;49:533-9.
17. Moore TJ, Dluhy RG, Williams GH, Cain JP. Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med 1976;85:731-4.
18. McCance DR, Russell CF, Kennedy TL, Hadden DR, Kennedy L, Atkinson AB. Bilateral adrenalectomy: low mortality and morbidity in Cushing's disease. Clin Endocrinol (Oxf) 1993;39:315-21.
19. Kaiser FE, Orth DN, Mukai K, Oppenheimer JH. A pituitary parasellar tumor with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides. J Clin Endocrinol Metab 1983;57:649-53.
20. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV. Pituitary carcinoma: a clinicopathological review. Neurosurgery 2005;56:1066-74.
21. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 2000;143:R1-6.
22. Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, Figarella-Branger D et al. Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol 2010;24:1835-18450.
23. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006;7:518-20.
24. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E et al. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 2006;65:552-3.
25. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009;71:226-33.
26. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011;117:454-62.
27. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012;76:769-75.
28. Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 2012;76:877-86.
29. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 2010;95:E280-90.